Used in the treatment of early-stage Alzheimer’s disease, lecanemab targets amyloid-beta plaques in the brain, helping to slow cognitive decline. It is administered intravenously and has shown efficacy in reducing disease progression in clinical trials involving patients with mild cognitive impairment or mild dementia due to Alzheimer’s. The drug supports disease modification by clearing amyloid aggregates, a hallmark of the condition, and is intended for use alongside diagnostic tools that confirm the presence of amyloid pathology.